Everything below concerns secretagogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-17. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
=== Traditional medicine and research === The bark, sap, roots, leaves, seeds, and flowers are used in traditional medicine. Research has examined how it might affect blood lipid profiles and insulin secretion. Extracts from leaves contain various polyphenols, which are under basic research to determine their potential effects in humans. Despite considerable preliminary research to determine if moringa components have bioactive properties, no high-quality evidence has been found to indicate that it has any effect on health or diseases.
=== Computational chemistry and MacroModel === In addition to his contributions to synthetic organic chemistry, Clark Still was an early pioneer in applying computational methods to the study of organic compounds. Conformational analysis was integral to Still's study of macrocyclic stereocontrol, and there was a general need for a fast and reliable computational method for predicting an organic molecule's lowest energy conformation. In order to address the problem, Still and coworkers reported a simple Monte Carlo method for searching conformational space in 1989. In this procedure, the internal coordinates for an organic molecule were varied at random, and the energy of the lowest energy conformation was determined after structure minimization. After each iteration, the minimum energy was compared to the values obtained previously in order to locate the global minimum; Still referred to this overall process as a Monte Carlo multiple-minimum search. In an effort to make molecular modeling more accessible to practicing organic chemists, Still developed the integrated software program MacroModel in 1986 in association with Columbia University. Dr. Wayne Guida, a senior postdoctoral researcher in Still's group at the time, described the development of this software package in the following way:
Director, Yorkshire Arboretum. For services to Tree Health and Plant Conservation. Liam Daniel Hackett. Founder and Chief Executive Officer, Ditch the Label. For services to Young People. Elizabeth Hall. Founder, The Hygiene Bank. For services to Tackling Hygiene Poverty. Penelope Evelyn Hall (Penelope Gravill). Speech and Language Therapist, Aberdeen Royal Infirmary. For services to the Treatment of Skull Base Tumours and Facial Palsies. Zahid Hamid. Lately Member, Peak District National Park Authority. For services to National Parks. Dr. Simon Leslie Hancock. Councillor, Pembrokeshire County Council. For services to the community in Pembrokeshire. Adam Peter Ritchie Handling. Chef, Ambassador of The GREAT Britain and Northern Ireland Campaign. For services to Hospitality and International Trade. Richard Heafield Harris. Fintech Innovator and Entrepreneur, Ensygnia (Onescan). For services to Fintech Innovation and to Global Technological Advancement. Valda Harris (Valda Jackson). Artist. For services to Art. Lesley Ann Hastings. For services to the community in Leeds, West Yorkshire. Philip Hugh Michael Haughton. Founder, Better Food. For services to Sustainable Food Initiatives and to the community in Bristol. Elizabeth Ann Hawkins. For services to Young People and to the community in Wirral, Merseyside. Lauren May Hemp. Footballer. For services to Association Football. Alasdair Cunningham Hendry. Senior Operations Manager, Forestry Commission. For services to Forestry and to Climate Change Mitigation. Alice Maria Hendy. Founder, R;pple Suicide Prevention Charity.
Sources: en.wikipedia.org
== History == Carfilzomib is derived from epoxomicin, a natural product that was shown by the laboratory of Craig Crews at Yale University to inhibit the proteasome. The Crews laboratory subsequently invented a more specific derivative of epoxomicin named YU101, which was licensed to Proteolix, Inc. Scientists at Proteolix invented a new, distinct compound that had potential use as a drug in humans, known as carfilzomib. Proteolix advanced carfilzomib to multiple phase I and II clinical trials, including a pivotal phase 2 clinical trial designed to seek accelerated approval. Clinical trials for carfilzomib continue under Onyx Pharmaceuticals, which acquired Proteolix in 2009. In January 2011, the FDA granted carfilzomib fast-track status, allowing Onyx to initiate a rolling submission of its new drug application for carfilzomib. In December 2011, the FDA granted Onyx standard review designation, for its new drug application submission based on the 003-A1 study, an open-label, single-arm phase IIb trial. The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma who had received at least two prior therapies, including bortezomib and either thalidomide or lenalidomide. Initial approval was based on response rate. Data demonstrating an overall survival benefit was demonstrated in the ENDEAVOR trial and approved by the FDA.
=== Spray drying === Spray-dried instant coffee is cheaper to produce and is preferred to freeze-drying in some cases because it allows larger scale economic production, shorter drying times, and produces fine, round, dust-sized particles. The particles as produced are too fine to use directly; they must first be steam-fused either in towers similar to spray dryers or by belt agglomeration to produce particles of suitable size. The process produces spherical particles about 300 micrometres (0.012 in) in size with a density of 0.22 g/cm3 through a nozzle atomizer. Various ways of nozzle atomization can be used, each having advantages and disadvantages. Wheels rotating at rapid speeds of about 20,000 rpm can process up to 6,000 pounds (2,700 kg) of solution per hour. The use of spray wheels requires that the drying towers have a wide radius to avoid the atomized droplets collecting onto the drying chamber walls. This process can be completed in 5 to 30 seconds, depending on factors such as temperature, size of particle, and diameter of chamber, and can reduce moisture content by over 70%.
To be competitive and independent from fluctuating support from (local) policy on the long run, biofuels should equal or beat the cost level of fossil fuels. Here, algae-based fuels hold great promise, directly related to the potential to produce more biomass per unit area in a year than any other form of biomass. The break-even point for algae-based biofuels is estimated to occur by 2025.
== Related peptides == This domain is also found in ghrelin, a growth hormone secretagogue synthesised by endocrine cells in the stomach. Ghrelin stimulates growth hormone secretagogue receptors in the pituitary. These receptors are distinct from the growth hormone-releasing hormone receptors, and, thus, provide a means of controlling pituitary growth hormone release by the gastrointestinal system. Erythromycin has an advantage over metoclopramide in gastric emptying due to lack of central nervous system side-effects. It is not approved by FDA to use for gastric emptying. For short duration for patients with diabetes and for those that must clear the stomach for any procedure, it may be used based on the physician's discretion with full understanding that it is not approved by FDA for this use.
Sources: en.wikipedia.org
Organised cooperative activity in India began with the enactment of Co-operative Credit Societies Act, 1904. The law was enacted on the recommendation of the Edward Law Committee and modelled partly on the Friendly Societies Act 1896. In the initial stage cooperative movement in India grew slowly. Following the enactment, British govt formed a cooperative rule on the basis of report given by Fredric Nicholson, a British officer of Madras region. The first cooperative society formed in TIRUR of Tiruvallur district of present day state of TamilNadu becoming the first cooperative of Asia. It was started by Adhinarayana Ayya on 30 August 1904.
In a momentum transfer pump (or kinetic pump), gas molecules are accelerated from the vacuum side to the exhaust side (which is usually maintained at a reduced pressure by a positive displacement pump). Momentum transfer pumping is only possible below pressures of about 0.1 kPa. Matter flows differently at different pressures based on the laws of fluid dynamics. At atmospheric pressure and mild vacuums, molecules interact with each other and push on their neighboring molecules in what is known as viscous flow. When the distance between the molecules increases, the molecules interact with the walls of the chamber more often than with the other molecules, and molecular pumping becomes more effective than positive displacement pumping. This regime is generally called high vacuum. Molecular pumps sweep out a larger area than mechanical pumps, and do so more frequently, making them capable of much higher pumping speeds. They do this at the expense of the seal between the vacuum and their exhaust. Since there is no seal, a small pressure at the exhaust can easily cause backstreaming through the pump; this is called stall. In high vacuum, however, pressure gradients have little effect on fluid flows, and molecular pumps can attain their full potential. The two main types of molecular pumps are the diffusion pump and the turbomolecular pump. Both types of pumps blow out gas molecules that diffuse into the pump by imparting momentum to the gas molecules.
=== Pharmacodynamics === Alazocine shows stereoselectivity in its pharmacodynamics. The (−)-enantiomer is a non-selective and high-affinity ligand of the μ-, κ-, and δ-opioid receptors (Ki = 3.0, 4.7, and 15 nM in guinea pig brain membranes) with very low affinity for the sigma σ1 receptor (Ki = 1,800–4,657 nM in guinea pig brain membranes). It acts as a moderate-efficacy partial agonist of the κ-opioid receptor (Ki = 0.4 nM, EC50 = 24 nM, and Emax = 66% for (±)-alazocine against the mouse receptor transfected in HEK293 cells) and as an antagonist of the μ-opioid receptor (Ki = 1.15 nM for (±)-alazocine against the mouse receptor transfected in HEK293 cells). It is also an agonist of the δ-opioid receptor with far lower potency (Ki = not reported, IC50 = 184 nM, and Imax = 68% for (±)-alazocine against the mouse receptor transfected in HEK293 cells). Conversely, the (+)-stereoisomer has little affinity for the opioid receptors (Ki for 1,900 nM, 1,600 nM, and 19,000 nM for the μ-, κ-, δ-opioid receptors in guinea pig brain membranes) and instead is a selective and high-affinity agonist of the σ1 receptor (Ki = 48–66 nM in guinea pig brain membranes). However, the (+)-enantiomer also shows moderate affinity for the dizocilpine (MK-801) or phencyclidine (PCP) site of the NMDA receptor (Ki = 587 nM in rat brain membranes relative to 45 nM for the σ1 receptor) and, hence, is an uncompetitive NMDA receptor antagonist as well at higher concentrations. As such, (+)-alazocine is only modestly selective as a ligand of the σ1 receptor.
== U.S. Patents == Polypeptides and biosynthetic pathways for the production of monatin and its precursors, U.S. Patent 9,034,610. Polypeptides and biosynthetic pathways for the production of monatin and its precursors, U.S. Patent 8,435,765. Polypeptides and biosynthetic pathways for the production of monatin and its precursors, U.S. Patent 8,372,989. Production of monatin and monatin precursors, U.S. Patent 8,206,955. Polypeptides and biosynthetic pathways for the production of monatin and its precursors. U.S. Patent 7,572,607. Production of 3-hydroxypropionic acid in recombinant organisms, U.S. Patent 6,852,517. Microbial production of 1,2-propanediol from sugar, U.S. Patent 6,303,352. Microbial production of 1,2-propanediol from sugar, U.S. Patent 6,087,140. Novel glycerol phosphatase with stereo-specific activity. U.S. Patent 5,733,749. Polysaccharide composition and process for preparing same. U.S. Patent 5,288,618. Galactomannan polysaccharide producing organism. U.S. Patent 5,130,249.
The American National Library of Medicine also stated in an article in 2018 that the consequences of FGM/C have both physiological and psychological complications, including short- and long-term complications. The method in which the procedure is performed may determine the extent of the short-term complications. If the process was completed using unsterile equipment, no antiseptics, and no antibiotics, the victim may have increased risk of complications. Primary infections include staphylococcus infections, urinary tract infections, excessive and uncontrollable pain, and hemorrhaging. Infections such as human immunodeficiency virus (HIV), Chlamydia trachomatis, Clostridium tetani, and herpes simplex virus (HSV) 2 are significantly more common among women who underwent Type 3 mutilation compared with other categories.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.